Description of Collaborative Activity: |
The ACTIV public-private partnership has evaluated hundreds of available therapeutic agents with potential application for COVID-19, prioritized the most promising candidates, designed and harmonized adaptive master protocols for ACTIV clinical trials, and selected numerous NIH-supported networks to launch these clinical trials to test prioritized therapeutic candidates. The ACTIV-1 master protocol is testing promising immune modulator compounds, a class of drugs that help minimize the deleterious effects of an overactive immune response to SARS-CoV-2 infection. This Phase 3 trial enrolled hospitalized adults with moderate to severe COVID-19 disease. The goal of the trial is to evaluate the safety and efficacy of each immune modulator when given as an add-on therapy to standard of care (SOC) at local clinics, which may include remdesivir (provided as part of the study to all participants), an antiviral approved for treatment of COVID-19The different treatments will be assessed with respect to illness severity, recovery speed, mortality, and hospital resource utilization. |
